Clinical Trial
Effects of combination therapy with bleomycin (NSC-125066) and dibromodulcitol (NSC-104800) on squamous cell carcinoma in man
- PMID: 4119907
Item in Clipboard
Clinical Trial
Effects of combination therapy with bleomycin (NSC-125066) and dibromodulcitol (NSC-104800) on squamous cell carcinoma in man
Cancer Chemother Rep.
1972 Oct.
No abstract available
Similar articles
-
[Clinical experience with bleomycin--a new cytostatic agent for cancer].Tidsskr Nor Laegeforen. 1971 Apr 10;91(10):714-6 passim. Tidsskr Nor Laegeforen. 1971. PMID: 5089800 Norwegian. No abstract available.
-
Bleomycin (NSC-125066): phase I clinical study.Cancer Chemother Rep. 1972 Apr;56(2):197-205. Cancer Chemother Rep. 1972. PMID: 4114485 No abstract available.
-
Initial clinical trial of dibromodulcitol (NSC-104800) in patients with advanced cancer.Cancer Chemother Rep. 1971 Dec;55(5):583-9. Cancer Chemother Rep. 1971. PMID: 5003621 Clinical Trial. No abstract available.
-
[Bleomycin, a new antitumour antibiotic in the treatment of neoplastic diseases].Wien Klin Wochenschr. 1972 Nov 17;84(46):737-43. Wien Klin Wochenschr. 1972. PMID: 4117777 Review. German. No abstract available.
-
Controlled studies with bleomycin in solid tumors and lymphomas.Prog Biochem Pharmacol. 1976;11:172-84. Prog Biochem Pharmacol. 1976. PMID: 63961 Review. No abstract available.
Cited by
-
Dibromodulcitol plus bleomycin compared with bleomycin alone in head and neck cancer.Cancer Chemother Pharmacol. 1982;8(2):171-3. doi: 10.1007/BF00255478. Cancer Chemother Pharmacol. 1982. PMID: 6179650 Clinical Trial.